Tag Archives: CLL

December, 2018

November, 2018

October, 2018

September, 2018

June, 2018

May, 2018

April, 2018

  • 9 April

    FDA Accepts NDA and Grants Priority Review to Verastem’s Duvelisib

    BOSTON–(BUSINESS WIRE)–Verastem, Inc. (NASDAQ:VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) for its lead product …

December, 2017